D. Shen

Articles by D. Shen

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

ByT. E. Witzig,Christine A. White, MD,Leo I. Gordon, MD,J. L. Murray,G. A. Wiseman,C. Emmanouilides,Myron S. Czuczman, MD,D. Shen,Pratik S. Multani, MD,A. J. Grillo-Lopez, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody covalently bound to the chelator tiuxetan, which can securely chelate yttrium-90. We performed a randomized controlled trial

Latest Updated Articles

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma
Published: March 1st 2001 | Updated:

D. Shen

Articles by D. Shen

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

Latest Updated Articles

Trending on CancerNetwork

Cancer Vaccine/Pembrolizumab Improves PFS in Treatment-Naive Melanoma

Relacorilant Regimen Improves PFS in Platinum-Resistant Ovarian Cancer

Sacituzumab Tirumotecan Improves Survival in Second-Line EGFR+ NSCLC

FDA Issues CRL for Dasatinib in CML/ALL

Frontline Immunotherapy Improves OS Vs BRAF/MEK Inhibitors in BRAF+ NSCLC